Attach importance to individualized treatment of diabetic macular edema

Q4 Medicine

中华眼底病杂志 Pub Date : 2020-02-25 DOI:10.3760/CMA.J.ISSN.1005-1015.2020.02.001

Chong Chen

{"title":"Attach importance to individualized treatment of diabetic macular edema","authors":"Chong Chen","doi":"10.3760/CMA.J.ISSN.1005-1015.2020.02.001","DOIUrl":null,"url":null,"abstract":"Diabetic macular edema (DME) is the most common retinopathy that seriously threatens the visual function of diabetic patients, and it represents a major cause of blindness especially among people in working age. Ocular VEGF inhibitors are most often used as a first line therapy for DME, and have revolutionary significance in improving visual outcomes. However, there remain 30%-50% patients who fail to respond to anti-VEGF treatment, and the need for frequent injections brings a substantial treatment burden to patients and society. Novel therapeutic strategies include improving efficacy and duration of anti-VEGF drugs, targeting inflammation, the plasma kallikrein-kinin system, the angiopoietin-Tie2 system, neurodegeneration and other alternative pathways, as well as using subthreshold and targeted laser therapy. It is still challenging in the individualized management of DME to identify non-responders to anti-VEGF drugs and to establish a standardized regimen for the switch from anti-VEGF therapy to anti-inflammatory or other alternative treatment. Further research and development of new therapies, as well as preventive and screening strategies, are needed to reduce the impact of diabetic retinopathy and DME on public health. \n \n \nKey words: \nMacular edema/therapy; Diabetic retinopathy/complications; Editorial","PeriodicalId":10103,"journal":{"name":"中华眼底病杂志","volume":"36 1","pages":"89-93"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华眼底病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1005-1015.2020.02.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetic macular edema (DME) is the most common retinopathy that seriously threatens the visual function of diabetic patients, and it represents a major cause of blindness especially among people in working age. Ocular VEGF inhibitors are most often used as a first line therapy for DME, and have revolutionary significance in improving visual outcomes. However, there remain 30%-50% patients who fail to respond to anti-VEGF treatment, and the need for frequent injections brings a substantial treatment burden to patients and society. Novel therapeutic strategies include improving efficacy and duration of anti-VEGF drugs, targeting inflammation, the plasma kallikrein-kinin system, the angiopoietin-Tie2 system, neurodegeneration and other alternative pathways, as well as using subthreshold and targeted laser therapy. It is still challenging in the individualized management of DME to identify non-responders to anti-VEGF drugs and to establish a standardized regimen for the switch from anti-VEGF therapy to anti-inflammatory or other alternative treatment. Further research and development of new therapies, as well as preventive and screening strategies, are needed to reduce the impact of diabetic retinopathy and DME on public health. Key words: Macular edema/therapy; Diabetic retinopathy/complications; Editorial

查看原文本刊更多论文

重视糖尿病性黄斑水肿的个体化治疗

糖尿病性黄斑水肿(DME)是严重威胁糖尿病患者视觉功能的最常见的视网膜病变，是导致失明的主要原因，尤其是在工作年龄人群中。眼部VEGF抑制剂最常被用作DME的一线治疗，在改善视力方面具有革命性的意义。然而，仍有30%-50%的患者对抗vegf治疗无效，频繁注射的需要给患者和社会带来了沉重的治疗负担。新的治疗策略包括提高抗vegf药物的疗效和持续时间，靶向炎症，血浆钾likrein-kinin系统，血管生成素- tie2系统，神经变性和其他替代途径，以及使用阈下和靶向激光治疗。在DME的个体化管理中，确定抗vegf药物无反应，并建立从抗vegf治疗转向抗炎或其他替代治疗的标准化方案仍然具有挑战性。需要进一步研究和开发新疗法以及预防和筛查战略，以减少糖尿病视网膜病变和二甲醚对公众健康的影响。关键词:黄斑水肿/治疗;糖尿病性视网膜病变/并发症;编辑

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华眼底病杂志 Medicine-Ophthalmology

CiteScore

0.40

自引率

0.00%

发文量

5383

期刊介绍： Chinese Journal of Ocular Fundus Diseases is the only scientific journal in my country that focuses on reporting fundus diseases. Its purpose is to combine clinical and basic research, and to give equal importance to improvement and popularization. It comprehensively reflects the leading clinical and basic research results of fundus disease disciplines in my country; cultivates professional talents in fundus disease, promotes the development of fundus disease disciplines in my country; and promotes academic exchanges on fundus disease at home and abroad. The coverage includes clinical and basic research results of posterior segment diseases such as retina, uveal tract, vitreous body, visual pathway, and internal eye diseases related to systemic diseases. The readers are medical workers and researchers related to clinical and basic research of fundus diseases. According to the journal retrieval report of the Chinese Institute of Scientific and Technological Information, the comprehensive ranking impact factor and total citation frequency of the Chinese Journal of Ocular Fundus Diseases have been among the best in the disciplines of ophthalmology, otolaryngology, and ophthalmology in my country for many years. The papers published have been included in many important databases at home and abroad, such as Scopus, Peking University Core, and China Science Citation Database (CSCD).